GREY:LXXGQ - Post by User
Comment by
Investor62on Jul 14, 2020 1:02pm
102 Views
Post# 31266195
RE:RE:RE:chicken sh!t investors selling
RE:RE:RE:chicken sh!t investors selling @gojuice: the math is easy and I have posted this in April:
Based on figures in their Company Presentation:
| Veterinary Diagnostics | $5.4B USD by 2024 |
| Food Safety | $24.4B USD by 2025 |
| Clinical Diagnostics | $12.9B USD by 2025 |
| Water Safety Testing | $3.5B USD by 2019 |
| Sample Prep Market | $9.3B USD by 2025 |
| PCR Market | $7B USD by 2026 |
| Genotyping Market | $11.8B USD |
| Total Market | $ 74.3B USD |
The margin 70 to 80 % seems to be amazing when they really have so low costs ($3 to $5). I do not have the actual numbers but looking at those forecasts will show how big the potential is when they go to commercialization and can get a good market share. From the above numbers one can calculate the net revenue when the margin is as high as they predict:
| Type | cost | sold | Margin $ | Margin % | Tot Rev 2025 | Net Rev 2025 |
| Vet | 5 | 40 | 35 | 88 | 5.4B | 4.725B |
| Food | 5 | 20 | 15 | 75 | 24.4B | 18.3B |
| Med | 5 | 60 | 55 | 92 | 12.9B | 11.825B |
| Others | 5 | 20 | 15 | 75 | 31.6B | 23.7B |
| Total | | | | | 74.3B | 58.55B |
Note that the above is NOT what LXG will achieve, this shows the total market share based on production cost of LXG / predicted selling prices of cartouche and does not include the revenue for the LXG Analyzer – but it seems this is the much lower part and the real cash cow is the selling of the cartouches.
Normally a share has a P.E. of 10 to 14 times, means the share price can be 10 to 14 times the revenue. The marketcap for all the testing companies is between USD 500 and 700 Billion by 2025 – how much LXG can be achieve is the main question.